MWA vs RFA for the Treatment of Moderate-sized Benign Thyroid Nodules

Last updated: May 23, 2024
Sponsor: The University of Hong Kong
Overall Status: Active - Recruiting

Phase

N/A

Condition

Thyroid Disease

Treatment

Ablation treatment of thyroid nodule

Clinical Study ID

NCT06426563
UW 24-141
  • Ages > 18
  • All Genders

Study Summary

Thyroid nodule is a common condition that affects up to 60% of the population. There is an estimated 10% lifetime probability of developing a thyroid nodule. Although most thyroid nodules are benign, up to 10-15% can enlarge to cause compressive symptoms including neck pressure and discomfort, dysphagia, dyspnea, and dysphonia. The conventional treatment for these benign but problematic nodules has been thyroidectomy. Although generally a low risk operation, thyroidectomy is associated with some risk for recurrent laryngeal nerve injury, bleeding, infection, and need for thyroid hormone supplementation. Since the early 2000s, ultrasound-guided percutaneous thermal ablation has emerged as a potential alternative treatment to surgery for benign thyroid nodules. Of the myriad ablation methods, the most commonly used techniques are radiofrequency ablation (RFA) and microwave ablation (MWA). [1-3] A growing body of evidence shows that RFA is an effective treatment for benign solid thyroid nodules, toxic adenomas, and thyroid cysts resulting in overall volume reduction ranges of 40-80% at 1 year, with durable resolution of compressive and hyperthyroid symptoms. However, RFA is not without its limitations. Radiofrequency waves can be limited by the heat sink effect and tissue char leading to longer procedure times and potentially less optimal outcomes in larger, hypervascular, and/or more cystic nodules.

Microwave ablation (MWA) is another ablative technique that uses electromagnetic energy waves to cause tissue hyperthermia and coagulative necrosis. It generally causes higher ablation temperatures than RFA and is less subject to the heat sink effect, and therefore can facilitate more efficient ablation procedures. Current evidence comparing RFA versus MWA for thyroid ablation was limited and was either retrospective, non-randomized [4-9], under-powered, or with an unequal baseline. The results from these studies were also conflicting, suggesting suboptimal quality of evidence and bias due to non-standardized technique of ablation across studies. To date, there is no randomized controlled trial comparing the efficacy and safety of RFA versus MWA for the treatment of benign thyroid nodules. Given the higher ablation temperatures, freedom from heat sink effect, and no influence from impedance changes during ablation, MWA may achieve different treatment efficacy.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Adult patients >/=18 years of age

  2. Nodule maximal diameter ≥2cm and nodule volume <20ml

  3. Nodule being predominantly solid (≥80% solid)

  4. Confirmed benign nature of nodules, either by : two benign fine needle biopsies,with the most recent biopsy performed within 1 year of enrollment in study or onebenign fine needle biopsy and low suspicion characteristics on ultrasound

  5. Both functional and non-functional nodules are eligible.

Exclusion

Exclusion Criteria:

  1. Cytologically indeterminate nodules

  2. Nodules with substernal extension or posterior extension that cannot be viewedsufficiently with ultrasound

  3. current pregnancy or cardiac arrhythmias; presence of pacemaker or any medicalcondition that renders patient unfit for thermal ablation

Study Design

Total Participants: 150
Treatment Group(s): 1
Primary Treatment: Ablation treatment of thyroid nodule
Phase:
Study Start date:
April 15, 2024
Estimated Completion Date:
June 30, 2028

Connect with a study center

  • Queen Mary Hospital

    Hong Kong, 00000
    Hong Kong

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.